Compliance With Vaccination Recommendations Among Patients With Multiple Myeloma: A Real World Experience

Compliance With Vaccination Recommendations Among Patients With Multiple Myeloma: A Real World Experience

Bibliographic Details
Main Authors:	Heinz Ludwig, Angela Meckl, Monika Engelhardt
Format:	Article
Language:	English
Published:	Wiley 2021-07-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000597

Similar Items

Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
by: Francesca Cottini, et al.
Published: (2021-02-01)

Lebanese Real-World Experience in Treating Multiple Myeloma: A Multicenter Retrospective Study
by: Fadi Nasr, et al.
Published: (2021-01-01)

Patient‐reported pain severity and health‐related quality of life in patients with multiple myeloma in real world clinical practice
by: Heinz Ludwig, et al.
Published: (2022-01-01)

Allogeneic Stem Cell Transplantation in Multiple Myeloma
by: Christine Greil, et al.
Published: (2021-12-01)

P948: REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA
by: Maria Nieves Lopez Muñoz, et al.
Published: (2023-08-01)

The real-world outcomes of multiple myeloma patients treated with daratumumab.
by: Agoston Gyula Szabo, et al.
Published: (2021-01-01)

Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A “real world” experience
by: Ludovica Fucci, et al.
Published: (2022-01-01)

Real‐world experience of novel multiple myeloma treatments in a large, single‐center cohort in Finland
by: Heidi Loponen, et al.
Published: (2023-11-01)

The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice
by: Rose Turner, et al.
Published: (2022-05-01)

Myeloma research on the move
by: Heinz Ludwig
Published: (2021-09-01)

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
by: Meera Mohan, et al.
Published: (2024-03-01)

BRAZILIAN REAL-WORLD MULTIPLE MYELOMA (MM) ELECTRONIC PLATFORM REGISTER PROJECT
by: E.Q. Crusoé, et al.
Published: (2020-11-01)

Vaccinations in patients with multiple sclerosis: a real-world, single-center experience
by: Elvira Sbragia, et al.
Published: (2022-11-01)

P09: ATTRITION RATES IN MULTIPLE MYELOMA UNDER REAL WORLD CONDITIONS – AN ANALYSIS FROM THE AUSTRIAN MYELOMA REGISTRY
by: MA Benda, et al.
Published: (2022-04-01)

Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum
by: Aya Nakaya, et al.
Published: (2023-01-01)

Attrition Rates in Multiple Myeloma Treatment under Real World Conditions—An Analysis from the Austrian Myeloma Registry (AMR)
by: Magdalena A. Benda, et al.
Published: (2023-02-01)

Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
by: Christopher J. Ferreri, et al.
Published: (2023-08-01)

Nationwide implementation of lenalidomide maintenance in multiple myeloma: A retrospective, real‐world study
by: Mads Harsløf, et al.
Published: (2024-04-01)

Real-world assessment of treatment multiple myeloma patients on the example of one hematology center
by: A. S. Luchinin, et al.
Published: (2023-10-01)

Real‐world multiple myeloma front‐line treatment and outcomes by transplant in the United States
by: Joshua Richter, et al.
Published: (2023-11-01)

Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma
by: Shang-Yi Huang, et al.
Published: (2019-01-01)

Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs.
by: Sarah Gooding, et al.
Published: (2015-01-01)

Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice
by: Jun Xia, et al.
Published: (2018-06-01)

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee
by: Shaji Kumar, et al.
Published: (2022-06-01)

Response to pneumococcal vaccination in multiple myeloma
by: Loïc Renaud, et al.
Published: (2019-07-01)

Real-world experience with isatuximab in the treatment of relapsed-refractory multiple myeloma: a case series from the Grand Duchy of Luxembourg
by: Sigrid De Wilde, et al.
Published: (2023-12-01)

Real-World Outcomes With Generic Pomalidomide in Relapsed Refractory Multiple Myeloma—Experience From a Tertiary Care Cancer Center
by: Suresh Kumar Bondili, et al.
Published: (2021-12-01)

Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary
by: Szilvia Lovas, et al.
Published: (2022-10-01)

Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel
by: Xavier Leleu, et al.
Published: (2023-02-01)

PB2105: LENALIDOMIDE MAINTENANCE IN MULTIPLE MYELOMA: A RETROSPECTIVE, NATIONWIDE, REAL-WORLD STUDY
by: Mads Harsløf, et al.
Published: (2023-08-01)

PB2028: TREATING MULTIPLE MYELOMA IN A RESOURCE-LIMITED SETTING: REAL-WORLD OUTCOMES
by: G. Martinez, et al.
Published: (2022-06-01)

Real‐world utilization and healthcare costs for multiple myeloma: A retrospective analysis of patients in Singapore
by: Diana Beatriz Bayani, et al.
Published: (2023-11-01)

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2023-07-01)

Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe
by: Evangelos Terpos, et al.
Published: (2022-10-01)

Real-world Duration of Use and Dosing Frequency of Daratumumab in Patients With Multiple Myeloma in the United States
by: Rafael Fonseca, MD, et al.
Published: (2023-10-01)

Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results
by: Luca Bertamini, et al.
Published: (2022-05-01)

High-dose chemotherapy following autologous hematopoietic stem cell transplantation for multiple myeloma in the real world setting. Single-center experience
by: Nikita E. Mochkin, et al.
Published: (2020-07-01)

Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies.
by: Julia Schueler, et al.
Published: (2013-01-01)

Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience
by: Vera A. Zherebtsova, et al.
Published: (2021-07-01)

Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network
by: Elisabetta Antonioli, et al.
Published: (2023-04-01)